{"id":"W2080237150","doi":"10.1111/bjd.13814","title":"Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)","year":2015,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":80,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"Novartis Pharma","keywords":"Secukinumab; Medicine; Psoriasis Area and Severity Index; Psoriasis; Dosing; Randomized controlled trial; Interleukin 17; Internal medicine; Dermatology; Cytokine; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004428375,0.0003188247,0.002237987,0.0005722216,0.0001383327,0.000111387,0.0003299927,0.0004422373,0.0000290181],"category_scores_gemma":[0.004150757,0.0002306576,0.000574621,0.0003092614,0.0002293701,0.0002294072,0.00005082356,0.0004817676,0.00002881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002900097,"about_ca_system_score_gemma":0.001020052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002861259,"about_ca_topic_score_gemma":0.0002963127,"domain_scores_codex":[0.9876742,0.009109713,0.002108716,0.000350819,0.0001419645,0.0006145788],"domain_scores_gemma":[0.996177,0.002338327,0.0009104038,0.0002528028,0.0002082183,0.0001132557],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9636871,0.001089404,0.00002967961,0.000002326483,0.0007013542,0.007621828,0.001622432,0.00007562303,0.003769846,0.00001706842,0.001147877,0.02023547],"study_design_scores_gemma":[0.9704822,0.001752098,0.0002242254,0.0001048903,0.0004719845,0.01829753,0.001605146,0.00002888172,0.004534053,0.0001578677,0.002126166,0.0002149849],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982196,0.008200681,0.0001798582,0.003372778,0.003935269,0.001919855,0.00005972084,0.00001648443,0.0001193233],"genre_scores_gemma":[0.9987035,0.0003136614,0.0001215164,0.0001654383,0.0002008216,0.0001990613,0.00002807341,0.00002285035,0.0002451083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02002048,"threshold_uncertainty_score":0.9405946,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01857271942566301,"score_gpt":0.2995247510734746,"score_spread":0.2809520316478116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}